ArticleClinical drug investigation2018
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.
Article in Clinical drug investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis.Blood vessels, thrombosis & hemostasis · 2026Article
- Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.Current heart failure reports · 2023Review
- Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.PloS one · 2023Article
- Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia.Frontiers in oncology · 2022Review
- Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.Frontiers in oncology · 2022Article
- Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge.Journal of clinical medicine · 2021Review
- Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase.Frontiers in oncology · 2021Article
- Potential ApproachesFrontiers in oncology · 2021Review
- Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.Acta haematologica · 2020Review
- CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1EBioMedicine · 2019Article
- Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.International journal of hematology · 2019Article
- Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.Therapeutic advances in hematology · 2019Review
- Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.Frontiers in oncology · 2019Review
- Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies.Hematology, transfusion and cell therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
29363026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.